Citizens Jmp Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price

Relay Therapeutics (NASDAQ:RLAY) had its price objective raised by analysts at Citizens Jmp from $15.00 to $17.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s target price would indicate a potential upside of 68.23% from the stock’s current price.

RLAY has been the topic of several other reports. Oppenheimer restated an “outperform” rating on shares of Relay Therapeutics in a research note on Monday. Guggenheim raised their price target on shares of Relay Therapeutics from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday. Wells Fargo & Company upped their price objective on shares of Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.17.

Relay Therapeutics Stock Down 0.2%

RLAY stock traded down $0.03 during mid-day trading on Tuesday, reaching $10.11. 93,429 shares of the company traded hands, compared to its average volume of 2,438,738. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -6.24 and a beta of 1.55. Relay Therapeutics has a fifty-two week low of $1.77 and a fifty-two week high of $11.49. The firm’s 50 day moving average price is $8.76 and its 200 day moving average price is $7.28.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.06. The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $4.34 million. On average, analysts anticipate that Relay Therapeutics will post -2.55 EPS for the current fiscal year.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 13,820 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the sale, the chief financial officer owned 250,996 shares of the company’s stock, valued at $1,912,589.52. The trade was a 5.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Donald A. Bergstrom sold 18,895 shares of Relay Therapeutics stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $143,979.90. Following the completion of the transaction, the insider owned 422,733 shares of the company’s stock, valued at approximately $3,221,225.46. This trade represents a 4.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 93,302 shares of company stock worth $724,355. 4.32% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RLAY. Torren Management LLC bought a new stake in shares of Relay Therapeutics during the fourth quarter valued at about $30,000. Smartleaf Asset Management LLC boosted its position in shares of Relay Therapeutics by 288.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Relay Therapeutics during the fourth quarter valued at approximately $46,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Relay Therapeutics by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after acquiring an additional 1,757 shares during the period. Finally, Abel Hall LLC bought a new stake in Relay Therapeutics during the 3rd quarter worth approximately $58,000. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.